The biodistribution and resulting pattern of transgene expression were determined following intravesical administration of an adenoviral vector carrying the luciferase reporter gene (AdLuc). Female BALB/c mice were subjected to intravesical instillation of 1 ϫ 10 9 or 5 ϫ 10 9 plaque-forming units of AdLuc. After sacrifice, transgene expression was detected in tissues using luciferase assays; vector DNA was detected by vector-specific polymerase chain reaction. These experiments showed very little vector dissemination outside of the bladder by this route of administration. High-level expression of the vector transgene in the bladder was found to diminish by severalfold after 3 days. In a supporting study, vector dissemination and resulting transgene expression were determined following tail vein injection of 5 ϫ 10 9 plaque-forming units of AdLuc. Vector was distributed to and expressed in every organ analyzed, with the highest concentration and level of expression observed in the liver.
G
ene therapy is one of the most promising new treatments for local-regional cancer. This field is rapidly expanding, with new genes, new vector systems, and new routes of administration moving into clinical development. An important component of the safety evaluation of these drugs involves the determination of their biodistribution and dissemination following administration by routes appropriate for particular clinical targets. Our interest lies in bladder cancer, in which locoregional treatment could be achieved by intravesical administration of a gene therapy vector. To determine vector biodistribution by this route of administration, an adenoviral vector carrying the firefly luciferase gene was instilled into the bladders of immunocompetent mice. Two methods were used to track the distribution of the vector from the bladder to other organs. The first method used a simple enzymatic assay to monitor the expression of the luciferase transgene in various organs. The second method determined the distribution of vector DNA using vector-specific polymerase chain reaction (PCR). The luciferase assay permitted quantification of the level of transgene expression in the various tissues, whereas PCR tracked the vector DNA independent of expression. The effects of two different dose levels on transgene expression were determined as well as the persistence of expression over a 3-week period. In a comparative study, vector distribution and resulting transgene expression were determined following systemic administration. The results of these studies extend those reported previously [1] [2] [3] [4] [5] [6] [7] to provide quantitative and qualitative analyses of vector biodistribution by two very different routes of administration.
MATERIALS AND METHODS

Animals and vectors
Female BALB/c mice were obtained from the Animal Production Area of the National Cancer Institute, Frederick Cancer Research Facility (Frederick, Md). The mice were maintained in a laminar air-flow cabinet under pathogen-free conditions and used at 6 -8 weeks of age. All facilities were approved by the American Association for the Accreditation of Laboratory Animal Care in accordance with the standards of the U.S. Department of Agriculture, the U.S. Department of Health and Human Services, and the National Institutes of Health. 8, 9 The adenoviral vector containing the Rous sarcoma viral promoter and luciferase cDNA has been described previously. 10 
Vector instillation
Mice were deprived of water for 12 hours prior to vector instillation and subsequently weighed. Animals were anesthe-tized with a single dose of sodium phenobarbital (25 mg/kg), and the urethra was catheterized with a 25-gauge plastic intravenous (i.v.) catheter to empty the bladder. Vector (1 ϫ 10 9 or 5 ϫ 10 9 plaque-forming units (PFU)) or phosphatebuffered saline (PBS) (control group) was introduced into the bladder, and the catheter was removed. The anesthetic permitted a dwell time of ϳ30 -45 minutes; mice were deprived of water for an additional 4 hours to maximize contact time. Mice were monitored daily for spontaneous activity and any signs of illness or morbidity. During the study period, all mice gained weight; there was no sign of any adverse effect. Mice were sacrificed by cervical dislocation, their weight was determined, and any anomalies were noted during necropsy.
To examine the biodistribution of vector via the i.v. route of administration, mice were injected in the tail vein with 5 ϫ 10 9 PFU of Ad Luc.
Collection of mouse organs for analysis
Mice were sacrificed at days 1, 3, 6, 13, and 21 after vector instillation; organs were harvested and stored at Ϫ70°C. When necessary, nonduplicated organs (e.g., bladders) were bisected and stored in separate tubes. One set representing the eight organs analyzed (i.e., one each of kidney, ureter, lung, adrenal, and ovary; one bisected half each of bladder, liver, and heart) was used for the PCR assay. The remaining set of organs was used for the luciferase assay. Scalpels and forceps were changed after each organ dissection or incision to avoid cross-contamination of the tissues.
Luciferase assays on mouse organs
Organs and half-organs were weighed, and 100 L of cell culture lysis reagent (25 mM tris(hydroxymethyl)aminomethane-phosphate (pH 7.8), 2 mM dithiothreitol, 2 mM 1,2-diaminocyclohexane-N,N,NЈ,NЈ-tetraacetic acid, 10% glycerol, and 1% Triton X-100) was added to each bladder, ureter, adrenal, and ovary specimen. A total of 400 L of the lysis reagent was added to each kidney, lung, and heart, and 2 mL was added to each liver. In studies comparing the results obtained with PCR with those obtained by luciferase assay, organs not duplicated were bisected; only one-half of a volume of lysis reagent was added. Tissues were homogenized at room temperature with a Teflon pestle, and cell debris was removed by centrifugation. A total of 10 L of cell-free extract was added to 100 L of luciferase assay substrate (Promega, Madison, Wis). Relative light units (RLU) were determined for 5 seconds using a Monolight 2010 Luminometer (Analytical Luminescence Laboratory, Ann Arbor, Mich).
PCR on mouse organs to detect the presence of the luciferase gene
Organs and half-organs were weighed, and those weighing Յ25 mg (half-bladders, ureters, and adrenals) were suspended in 180 L of ATL (Amp tissue lysis) buffer (QIAamp Tissue Kit, Qiagen, Chatsworth, Calif) and 20 L of proteinase K (17 mg/mL). Volumes of ATL buffer and proteinase K were proportionate for the heavier organs. Organs were homogenized using Teflon tissue grinders. A 200-L aliquot of each organ was incubated at 55°C for 1 hour and subsequently placed at room temperature; next, 20 L of ribonuclease A (20 mg/mL) was added. After a 5-minute incubation at room temperature, 200 L of QIAamp AL (Amp lysis) buffer was added, and the sample was incubated at 70°C for 10 minutes. A total of 210 L of 100% ethanol was added to each sample. Samples were mixed thoroughly and placed into QIAamp spin-columns. After several washing steps, the DNA was eluted with 100 L of 0.5 ϫ TE. 11 The DNA in each sample was quantified using Hoechst H 33258 dye and a fluorometer (Hoefer Dynaquant 200, Hoefer Scientific Instruments, San Francisco, Calif) according to the manufacturer's instructions.
Each DNA sample was used in a PCR that amplified a 375-base pair fragment of the firefly luciferase transgene. Reactions contained 200 ng of sample DNA, 16 pmol of each primer (5Ј-TGGGCGCGTTATTTATCGGAGTT, 5Ј-TGACGCAGGCAGTTCTATG), 50 mM KCl, 10 mM tris(hydroxymethyl)aminomethane (pH 8.3, 25°C), 2 mM MgCl 2 , 200 M of each deoxynucleoside triphosphate, and 5 U of AmpliTaq Gold (Perkin Elmer, Branchburg, NJ) in a 50-L volume. Reactions were incubated at 96°C for 15 minutes followed by 35 cycles of 30 seconds at 96°C, 20 seconds at 55°C, and 50 seconds at 72°C. After the final cycle, a 6-minute incubation at 72°C was performed. Loading dye was added to each of the reactions, which were electrophoresed in a 4.0% precast Nusieve gel (FMC Bioproducts, Rockland, Me) containing 0.5 g/mL ethidium bromide, visualized with an ultraviolet transilluminator, and photographed.
The sensitivity of the reactions was determined by adding decreasing amounts of purified Ad Luc vector DNA (1 ng, 1 pg, 100 fg, 10 fg, and 1 fg) into 220 ng of mouse genomic DNA (Sigma, St. Louis, Mo) in separate tubes for side-by-side amplification reactions with our test materials. A sample without any vector was run as a negative control to detect any contamination. Comparison of vector biodistribution following systemic administration as determined by reporter gene activity with that determined by PCR analysis. In this experiment, 5 ϫ 10 9 PFU of Ad Luc was administered to each of three mice by tail vein injection. After 72 hours, organs were harvested and tested for the presence of vector by luciferase assays and PCR. PCR results are expressed as an estimate of the amount of vector DNA present in the PCR as described above. ϩϩϩ, Ն2500 copies of vector; ϩϩ, 250 copies of vector; ϩ, 25 copies of vector; Ϫ, no detectable vector. Luciferase activity is expressed in terms of RLU per mg of tissue.
RESULTS AND DISCUSSION
A combination of PCR and reporter gene analyses permits detection and quantification of vector biodistribution following systemic administration An adenoviral vector carrying the luciferase reporter gene (Ad Luc) was used to determine the pattern of vector biodistribution and transgene expression following i.v. administration to immunocompetent mice. The biodistribution resulting from this route of administration was expected to be widespread and provided a basis for comparison with that obtained following intravesical administration, a route expected to result in a more restricted pattern. For systemic administration, three animals were injected with 5 ϫ 10 9 PFU of AdLuc via the tail vein. The animals were sacrificed after 72 hours, and the organs were harvested for PCR and luciferase assays. As seen in Figure 1 , luciferase activity was detected in most organs analyzed. The majority (ϳ10 5 RLU/mg) was found in liver, with only low to modest expression (Յϳ10 2 RLU/mg) in any other tissue. Background for this assay is Յ10 RLU (see Fig 6c) . These data are consistent with other published studies that examined the biodistribution of tail vein-injected AdLuc vector. 2 All organs were also found to be positive for the presence of vector DNA as determined by PCR analysis (Fig 2) . Although this analysis is semiquantitative at the lower limits of detection, the ability to quantitate biodistribution based on the intensity of the amplicons is lost at ϳ2500 gene copies (100 fg) per 200 ng of cellular DNA. The strength of the nonquantitative PCR assay is clearly its ability to detect an extremely small vector load resident in a given tissue; however, this assay provides only a gross indication of relative distribution of vector DNA and no indication of subsequent transgene expression (compare Figs 1 and 2 ).
Luciferase activity in the bladder declines in a timedependent manner following intravesical administration To support the main biodistribution study, a 15-animal, 21-day experiment examined the stability of luciferase gene expression in bladder epithelial tissue. Each of the animals was treated intravesically with 5 ϫ 10 9 PFU of AdLuc. Three animals were sacrificed on day 1, and the bladders were harvested and assayed for luciferase activity as well as for the presence of vector DNA sequences. Identical procedures were performed on days 3, 6, 13, and 21. Maximal luciferase activity and PCR signal were seen after 24 hours (Figs 3 and 4) . Lucif- Figure 2 . Results of PCR analysis of DNA isolated from organs of three mice treated with 5 ϫ 10 9 PFU of Ad Luc by tail vein injection. Lanes 1, 8, 15, and 22 contain molecular weight standards (Promega). Lanes 2-7 contain decreasing amounts of vector DNA (1 ng, 1 pg, 100 fg, 10 fg, 1 fg, and 0 fg, respectively) in the reactions. Lanes 9 -14 contain the products of PCR amplifications of DNA isolated from the organs (bladder, kidney, liver, lung, ureter, and heart, respectively) of the first mouse. Lanes 16 -21 and 23-28 are identical with lanes 9 -14, except that they contain DNA isolated from the second and third mouse, respectively. Lane 29 represents a negative control, with water as the test sample.
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erase activity was still high on day 3, although there was quantifiably less vector by PCR. Although there was considerable quantitative variation among the animals tested, both expression levels and the intensity of the PCR signal decreased over time, particularly with regard to the signals obtained after 24 hours. For example, the average luciferase activity was two orders of magnitude lower on day 21 than on day 1.
It is worth noting that some bladders that showed apparent luciferase activity at later timepoints had no vector DNA detectable by PCR (and vice versa). This result is consistent with an uneven distribution or uptake of vector in the mouse bladder. In these experiments, the bladder was bisected; each half-bladder was used in one of the two assays. Other studies have shown that adenoviral vectors can distribute unevenly in bladder tissue. 1 The potential exists, therefore, for unevenly transduced tissue to partition unevenly on bisection, with one of the bisected halves carrying the majority of the transduced cells and the other half carrying virtually none. In this study, the small sample size and possible asymmetric uptake limit us to the general conclusion that transgene expression and the intensity of the PCR signal decrease over time following intravesical administration.
Little vector distributes outside the bladder following intravesical administration: Results of a pilot biodistribution study AdLuc (5 ϫ 10 9 PFU) was administered intravesically to each of three animals. The animals were sacrificed after 24 hours, and eight organs/organ pairs were harvested for PCR and luciferase assays. Significant luciferase activity was detected in the bladder (the target organ), verifying that the bladder could be transduced by vector and express a reporter gene (Fig 5) . The luciferase activity detected per milligram of bladder tissue was far greater than that found in any other organ examined. Consistently high concentrations of vector DNA, as determined by PCR, were found in the bladder, with only sporadic appearance at much lower levels in other organs. Of the other organs examined, only one kidney and one ureter showed any appreciable level of luciferase activity or positive PCR signal. The positive PCR signals were not only sporadic but asymmetrical (i.e., one kidney positive, the other negative) and may represent uneven reflux from the bladder. Because the PCR analysis is semiquantitative near the lower limit of detection (i.e., up to ϳ2500 vector copies (100 fg) per 200 ng of cellular DNA), the positive PCR signal seen in the non-bladder organs (with the exception of the ureter from mouse 3) occurred at a very low level (Ͻ10 fg per 200 ng of cellular DNA). The sporadic appearance of vector DNA in the nongenitourinary tissues may be a consequence of a physical trauma that occurred during the instillation procedure. A disruption of the bladder epithelium may allow a small amount of vector to pass into the circulation and distribute to various tissues, thus leading to the sporadic appearance of vector sequences in other organs.
Reporter gene activity following intravesical administration was not dose-dependent: A comparison of reporter gene activity at two dose levels Nine animals were randomly divided into three cohorts for the study. Each cohort received an intravesical administration of 1 ϫ 10 9 PFU of AdLuc, 5 ϫ 10 9 PFU of AdLuc, or PBS. Organs from the PBS-treated animals (Fig 6c) established the background level of activity for the assay as Յ10 RLU/mg tissue for all organs tested. All of the animals treated with the Ad Luc vector had readily detectable levels of luciferase activity in the bladder (Fig 6, a and b) . However, virtually no luciferase activity was detected in any other organ, with the exception of the right kidney of one higher dose animal. This small amount of expression (ϳ40 RLU/mg) was found in only one kidney, suggesting an asymmetric reflux of the vector into the kidney during administration.
There was no apparent dose-dependence to the amount of luciferase activity found in the bladders, although only two dose levels differing by a factor of five have been assayed. This may mean that expression of the transgene in this model might be limited by vector uptake. The bladder epithelium is covered by a proteoglycan layer, the glycosaminoglycan (GAG) layer, which protects the epithelium and probably limits adenoviral transduction. Removal of the GAG layer by HCl treatment increases gene expression in the bladder by Ͼ100-fold (our unpublished results), likely due to increased adenoviral delivery to the normal epithelium. Comparison of two methodologies to support biodistribution studies of adenoviral vectors At the lower limit of detection (25-2500 copies of a gene), the PCR assay employed in these experiments gave semiquantitative results. Like the luciferase data from the bladder administration, the PCR results showed that vector was almost not detectable in any organ other than the bladder, yet the occasional organ yielded a faint positive band that was recognizable on the gel. It could be estimated from the intensity of the band that the gene copy number in certain PCR experiments was between 25 and 2500 copies. Either this material was not expressing sufficient quantities of luciferase to be detected by an enzymatic assay or it was degraded to the point where gene expression was impossible. PCR would therefore be better suited to applications requiring an exquisitely high degree of sensitivity (i.e., those requiring detection of the smallest level of DNA). As the degree of DNA delivery to an organ increases, however, the luciferase assay is probably better suited to examine biodistribution because of its ability to yield quantitative data over a five-log linear range, whereas PCR would simply yield a positive or negative result.
When comparing the two routes of administration, it is quite apparent that little vector is distributed beyond the bladder following intravesical administration. This result is markedly different from that obtained by tail vein injection, where biodistribution is widespread.
